NIH institutes with a published FY2026 payline
0 of 27
NIH ended score cutoffs under its Unified Funding Strategy
Grantsights original data · Updated October 1, 2026
Every NIH institute's FY2026 payline status, success rates by institute for research grants, R01s, K awards and F fellowships, and NSF funding rates by directorate and division. Each figure comes from NIH's or NSF's own tables and is checked against the source before publication.
NIH success rates: NIH Data Book, FY2021 to FY2025, data last updated February 19, 2026. FY2026 policies: institute pages on grants.nih.gov, read October 1, 2026. NSF: FY2025 agency totals, FY2024 directorate and division rates. The page and CSV are licensed CC BY 4.0.
No NIH institute publishes a payline for FY2026. NIH funded 13.0% of research grant applications in FY2025, down from 18.5%, as applications rose 13% and awards fell 20%. New R01s did worse at 9.9%. NSF funded 19% of proposals.
NIH institutes with a published FY2026 payline
0 of 27
NIH ended score cutoffs under its Unified Funding Strategy
NIH research grant success rate, FY2025
13.0%
8,161 of 62,592 applications, down from 18.5%
New R01 success rate, FY2025
9.9%
3,405 of 34,491 new R01 applications
NSF funding rate, FY2025
19%
8,377 of 43,532 proposals, down from 26%
NIH, FY2026
No NIH institute publishes a payline for FY2026. NIH's funding decisions page says institutes "will no longer employ these cutoff points in overall impact scores to determine which applications to fund." Four institutes say so on their own page. The rest describe what they weigh instead, and many publish budget cuts and award-length limits that matter as much as the score. Every page also notes that NIH is operating under a continuing resolution (NOT-OD-26-131).
| Institute | Payline | What the FY2026 policy says | Source |
|---|---|---|---|
| FICFogarty International Center | Payline: None (NIH-wide) | Fogarty funds through its own solicitations only and does not accept unsolicited investigator-initiated applications. | FIC policy |
| NCATSNational Center for Advancing Translational Sciences | Payline: None (NIH-wide) | Competing award levels follow program and grants-management recommendations. Most continuing grants are paid at 90% during the continuing resolution. | NCATS policy |
| NCCIHNational Center for Complementary and Integrative Health | Payline: None (NIH-wide) | Each competing application is assessed individually; aims and budgets can be adjusted and no inflation increases are added. | NCCIH policy |
| NCINational Cancer Institute | Payline: None (stated) | New R01s with direct costs over $250,000 in any year are generally funded 17% below the study section's recommended level. Smaller new R01s are cut 6.5% (up to $175,000) or 8.5%. | NCI policy |
| NEINational Eye Institute | Payline: None (stated) | Each council round, NEI ranks applications within program areas and builds a funding plan from program recommendations. | NEI policy |
| NHGRINational Human Genome Research Institute | Payline: None (NIH-wide) | Parent-announcement R01s are generally funded for four years. | NHGRI policy |
| NHLBINational Heart, Lung, and Blood Institute | Payline: None (stated) | Investigator-initiated R01s are funded for up to four years. Early stage investigators and clinical studies that need longer are the exceptions. | NHLBI policy |
| NIANational Institute on Aging | Payline: None (NIH-wide) | Competing awards are cut 16% on average. R03, R21, R15, R36 and new or early stage investigator awards are exempt. | NIA policy |
| NIAAANational Institute on Alcohol Abuse and Alcoholism | Payline: None (NIH-wide) | Administrative reductions are applied to the direct costs of all competing grants. Early stage investigators get special consideration. | NIAAA policy |
| NIAIDNational Institute of Allergy and Infectious Diseases | Payline: None (stated) | Competing awards can be funded at up to 100% of the approved level. Select R01s are multi-year funded for up to four years. | NIAID policy |
| NIAMSNational Institute of Arthritis and Musculoskeletal and Skin Diseases | Payline: None (NIH-wide) | NIAMS is unlikely to fund a PI who already holds more than three active R01-equivalent grants. | NIAMS policy |
| NIBIBNational Institute of Biomedical Imaging and Bioengineering | Payline: None (NIH-wide) | Parent R01s are capped at four years. ESI and modular budgets are cut about 10%; other budgets about 20%. | NIBIB policy |
| NICHDEunice Kennedy Shriver National Institute of Child Health and Human Development | Payline: None (NIH-wide) | New competing R01s are reduced 14% on average below the recommended level. | NICHD policy |
| NIDANational Institute on Drug Abuse | Payline: None (NIH-wide) | New and competing awards are held near FY2025 average cost. Renewals generally can't grow more than 10% over the prior award. | NIDA policy |
| NIDCDNational Institute on Deafness and Other Communication Disorders | Payline: None (NIH-wide) | During the continuing resolution, NIDCD limits new awards. Categorical R01s are paid at 85% of the recommended level, modular R01s at 100%. | NIDCD policy |
| NIDCRNational Institute of Dental and Craniofacial Research | Payline: None (NIH-wide) | Modular R01s are reduced at least 10% below the request; non-modular R01s at least 15%. | NIDCR policy |
| NIDDKNational Institute of Diabetes and Digestive and Kidney Diseases | Payline: None (NIH-wide) | R01s averaging under $500,000 a year in direct costs get priority, and PIs with substantial other support are deprioritized. Awards may be trimmed to a four-year average. | NIDDK policy |
| NIEHSNational Institute of Environmental Health Sciences | Payline: None (NIH-wide) | Priority goes to strategic-plan fit and new, early stage and at-risk investigators. Large unspent balances can trigger budget offsets. | NIEHS policy |
| NIGMSNational Institute of General Medical Sciences | Payline: None (NIH-wide) | NIGMS is unlikely to give a PI more than one NIGMS R01 and generally prioritizes MIRA (R35) over R01s. | NIGMS policy |
| NIMHNational Institute of Mental Health | Payline: None (NIH-wide) | Decisions weigh strategic-plan fit, the full peer review record and portfolio balance, with priority for early stage investigators. | NIMH policy |
| NIMHDNational Institute on Minority Health and Health Disparities | Payline: None (NIH-wide) | Established investigators already holding three R01, P50 or U54 projects across NIH won't be considered. ESI R01s are funded at 100%. | NIMHD policy |
| NINDSNational Institute of Neurological Disorders and Stroke | Payline: None (NIH-wide) | Non-modular R01s take a 20.5% administrative reduction. Applications over $500,000 a year need to meet two of three priority tests. | NINDS policy |
| NINRNational Institute of Nursing Research | Payline: None (NIH-wide) | Competing R01 budgets are cut 10% on average, with no standard cut for early stage investigators. | NINR policy |
| NLMNational Library of Medicine | Payline: None (NIH-wide) | Modular R01s, R21s and R15s are paid at 90% of the recommended level; categorical R01s at 85%. | NLM policy |
| Common FundNIH Common Fund | Payline: None (NIH-wide) | No standard budget reduction; each funding opportunity sets its own terms. | Common Fund policy |
| ORIPOffice of Research Infrastructure Programs | Payline: None (NIH-wide) | Most K01 and R24 awards are limited to four years. | ORIP policy |
| BRAINBRAIN Initiative | Payline: None (NIH-wide) | Continuing awards are paid at 90%, except R21, R25, R34 and SBIR/STTR at 100%. | BRAIN policy |
OBSSR, ODP and THRO also post FY2026 pages, but they co-fund grants that other institutes select and don't take applications directly. Policies are summarized in plain language; read the institute page before planning a budget.
NIH, FY2021 to FY2025
Research project grants (RPGs) cover R01s, R21s, P01s, U01s and the other investigator research mechanisms NIH lists in its definition. In FY2025, NIH reviewed 62,592 RPG applications, 13% more than in FY2024, and made 8,161 awards, 20% fewer. Both moves pushed the rate down at almost every institute. Sorted by FY2025 rate.
| Institute | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | Change, FY2024 to FY2025 |
|---|---|---|---|---|---|---|
| All NIH | 19.1%11,229 of 58,872 | 20.7%11,311 of 54,571 | 21.3%11,052 of 51,883 | 18.5%10,265 of 55,418 | 13.0%8,161 of 62,592 | -5.5 pts |
| NIGMS | 33.4%1,185 of 3,551 | 35.8%1,207 of 3,368 | 36.3%1,150 of 3,166 | 31.5%1,038 of 3,295 | 25.9%1,012 of 3,909 | -5.6 pts |
| ORIP | 25.9%15 of 58 | 27.1%16 of 59 | 34.0%18 of 53 | 34.0%16 of 47 | 22.6%14 of 62 | -11.4 pts |
| NIDCR | 21.8%198 of 910 | 21.0%184 of 878 | 22.0%191 of 869 | 19.1%173 of 906 | 18.2%177 of 971 | -0.9 pts |
| NEI | 24.8%300 of 1,208 | 25.6%316 of 1,235 | 26.2%310 of 1,183 | 26.7%329 of 1,233 | 17.6%240 of 1,362 | -9.1 pts |
| NIDCD | 24.0%180 of 750 | 25.0%191 of 764 | 26.9%183 of 680 | 25.0%186 of 744 | 17.5%155 of 888 | -7.5 pts |
| FIC | 13.8%22 of 159 | 20.9%29 of 139 | 22.3%21 of 94 | 19.8%18 of 91 | 16.8%18 of 107 | -3.0 pts |
| NHLBI | 20.5%916 of 4,479 | 21.3%984 of 4,621 | 21.1%908 of 4,301 | 19.7%952 of 4,833 | 16.6%889 of 5,341 | -3.1 pts |
| NIAID | 17.5%1,582 of 9,061 | 17.3%1,230 of 7,126 | 20.8%1,405 of 6,750 | 18.3%1,280 of 7,001 | 15.4%1,202 of 7,792 | -2.9 pts |
| NCATS* | 14.7%19 of 129 | 20.4%37 of 181 | 26.8%52 of 194 | 14.2%45 of 316 | 15.0%46 of 307 | 0.8 pts |
| NICHD | 18.4%509 of 2,766 | 17.3%498 of 2,873 | 18.8%500 of 2,653 | 18.9%500 of 2,651 | 14.0%411 of 2,928 | -4.9 pts |
| NIDA | 14.7%309 of 2,106 | 19.5%406 of 2,085 | 22.1%399 of 1,808 | 19.3%382 of 1,984 | 13.6%302 of 2,215 | -5.7 pts |
| NIEHS | 14.4%144 of 997 | 16.7%160 of 960 | 15.1%134 of 885 | 16.4%165 of 1,008 | 13.0%125 of 961 | -3.4 pts |
| NIBIB | 17.2%217 of 1,260 | 21.5%239 of 1,110 | 17.7%187 of 1,056 | 16.1%175 of 1,084 | 12.8%188 of 1,464 | -3.3 pts |
| NIAMS | 17.6%272 of 1,547 | 18.4%285 of 1,551 | 17.8%241 of 1,355 | 18.0%250 of 1,392 | 12.5%175 of 1,401 | -5.5 pts |
| NIAAA | 17.1%143 of 835 | 27.1%204 of 752 | 30.5%219 of 717 | 22.6%148 of 655 | 12.4%87 of 703 | -10.2 pts |
| NIDDK | 22.6%788 of 3,493 | 21.1%641 of 3,045 | 22.8%706 of 3,095 | 20.5%672 of 3,276 | 12.0%422 of 3,528 | -8.5 pts |
| NINDS | 19.7%857 of 4,346 | 21.8%947 of 4,350 | 20.9%904 of 4,319 | 15.9%736 of 4,626 | 11.5%597 of 5,187 | -4.4 pts |
| NIMH | 22.1%647 of 2,923 | 24.3%673 of 2,769 | 21.7%579 of 2,671 | 21.1%609 of 2,890 | 10.7%351 of 3,271 | -10.4 pts |
| NINR | 12.6%67 of 533 | 15.4%60 of 390 | 16.9%54 of 319 | 15.7%54 of 345 | 9.9%28 of 284 | -5.8 pts |
| NCI | 13.7%1,333 of 9,701 | 15.2%1,358 of 8,932 | 15.9%1,369 of 8,618 | 13.7%1,245 of 9,117 | 9.6%973 of 10,156 | -4.1 pts |
| NLM | 11.9%36 of 303 | 15.3%35 of 229 | 14.8%25 of 169 | 13.1%29 of 221 | 8.4%25 of 299 | -4.7 pts |
| NIA | 24.2%1,073 of 4,433 | 25.3%1,158 of 4,582 | 24.0%1,057 of 4,402 | 18.0%922 of 5,130 | 8.0%511 of 6,378 | -10.0 pts |
| NHGRI | 24.7%140 of 567 | 25.1%97 of 386 | 22.0%96 of 437 | 19.6%89 of 455 | 7.3%47 of 645 | -12.3 pts |
| NCCIH* | 11.1%45 of 404 | 14.8%46 of 311 | 14.4%43 of 299 | 16.0%49 of 306 | 7.1%25 of 351 | -8.9 pts |
| Common Fund | 8.8%140 of 1,595 | 11.8%121 of 1,026 | 14.6%166 of 1,138 | 7.2%85 of 1,187 | 5.9%81 of 1,377 | -1.3 pts |
| NIMHD* | 11.2%84 of 750 | 17.2%137 of 797 | 18.8%120 of 637 | 13.5%79 of 586 | 3.7%25 of 670 | -9.8 pts |
* NIH's table marks the FY2025 rows for NCATS, NCCIH, NIMHD with asterisks but its workbook doesn't say why. Treat those rates with extra care. NIH's separate Type 1 Diabetes program row (35 of 35 funded in FY2025) is in the CSV but left out here.
NIH, FY2023 to FY2025
Across NIH, 11.3% of R01 and R37 applications were funded in FY2025, down from 16.6% in FY2024 and 19.1% in FY2023. New R01s, the first-time applications most investigators care about, did worse at 9.9%. The R01 and R37 columns add new, renewal and revision applications together, the closest public match to an institute's R01 count. Gray cells have fewer than 20 applications.
| Institute | R01 and R37, FY2023 | FY2024 | FY2025 | New R01s only, FY2025 |
|---|---|---|---|---|
| NIGMS | 23.2%363 of 1,563 | 14.4%212 of 1,477 | 8.3%110 of 1,323 | 6.1%66 of 1,087 |
| ORIP | 15.4%2 of 13 | 25.0%1 of 4 | 14.3%1 of 7 | 16.7%1 of 6 |
| NIDCR | 17.5%75 of 429 | 17.2%80 of 465 | 12.6%65 of 517 | 11.1%52 of 469 |
| NEI | 26.5%223 of 840 | 26.7%233 of 874 | 16.8%160 of 955 | 12.8%98 of 765 |
| NIDCD | 27.1%121 of 446 | 23.9%118 of 494 | 16.8%96 of 571 | 13.7%65 of 473 |
| FIC | 31.8%7 of 22 | 23.5%8 of 34 | 12.5%3 of 24 | 12.5%3 of 24 |
| NHLBI | 19.8%714 of 3,598 | 18.6%728 of 3,914 | 15.5%693 of 4,476 | 14.6%596 of 4,094 |
| NIAID | 17.8%632 of 3,557 | 16.2%593 of 3,654 | 14.5%580 of 3,992 | 12.8%462 of 3,613 |
| NICHD | 17.0%259 of 1,526 | 17.6%270 of 1,531 | 15.3%249 of 1,628 | 14.1%212 of 1,508 |
| NIDA | 21.1%207 of 980 | 16.8%171 of 1,017 | 12.1%139 of 1,150 | 11.5%125 of 1,089 |
| NIEHS | 13.7%72 of 526 | 13.9%87 of 626 | 12.4%72 of 580 | 11.9%66 of 553 |
| NIBIB | 21.2%95 of 448 | 20.6%85 of 412 | 16.8%101 of 601 | 16.1%88 of 545 |
| NIAMS | 16.5%139 of 844 | 16.7%151 of 906 | 14.6%144 of 984 | 13.5%121 of 896 |
| NIAAA | 29.4%131 of 445 | 19.7%81 of 411 | 13.6%61 of 450 | 14.2%58 of 408 |
| NIDDK | 20.6%554 of 2,687 | 18.7%529 of 2,824 | 10.4%330 of 3,160 | 9.0%253 of 2,823 |
| NINDS | 18.8%484 of 2,569 | 15.4%432 of 2,814 | 9.9%321 of 3,249 | 8.6%251 of 2,932 |
| NIMH | 20.3%329 of 1,622 | 22.1%393 of 1,779 | 10.0%196 of 1,958 | 9.3%169 of 1,823 |
| NINR | 21.4%40 of 187 | 15.3%34 of 222 | 9.8%19 of 194 | 9.4%18 of 191 |
| NCI | 16.4%912 of 5,561 | 12.8%746 of 5,826 | 9.0%594 of 6,636 | 6.9%432 of 6,278 |
| NLM | 17.9%22 of 123 | 13.1%22 of 168 | 8.5%17 of 199 | 8.2%15 of 184 |
| NIA | 18.8%473 of 2,511 | 14.6%425 of 2,906 | 5.4%206 of 3,805 | 5.0%183 of 3,645 |
| NHGRI | 23.1%57 of 247 | 17.0%45 of 264 | 10.6%38 of 359 | 9.1%30 of 328 |
| NCCIH | none | none | 7.2%11 of 153 | 7.4%11 of 149 |
| Common Fund | 4.1%6 of 145 | 6.0%7 of 117 | 3.6%6 of 166 | 3.6%6 of 166 |
| NIMHD | none | none | 4.9%22 of 447 | 4.6%20 of 438 |
NIGMS funds most investigator research through MIRA (R35) awards, so its R01 rate understates its overall odds. Use its research grant rate above.
NIH, FY2025
NIH-wide in FY2025: K01 22.5%, K08 29.7%, K23 30.5% and K99 19.5%. Institute counts are small, so one year can swing hard. The CSV includes every year from FY2021, so several years can be added together for a steadier rate. Gray cells have fewer than 20 applications.
| Institute | K01 | K08 | K23 | K99 |
|---|---|---|---|---|
| NIGMS | none | 66.7%2 of 3 | 50.0%1 of 2 | 16.4%23 of 140 |
| ORIP | 22.2%2 of 9 | none | none | none |
| NIDCR | 0.0%0 of 4 | 38.5%5 of 13 | 80.0%4 of 5 | 18.2%6 of 33 |
| NEI | none | 55.6%5 of 9 | 50.0%3 of 6 | 30.4%14 of 46 |
| NIDCD | 0.0%0 of 3 | 50.0%3 of 6 | 57.1%8 of 14 | 30.0%6 of 20 |
| FIC | 11.1%1 of 9 | none | none | none |
| NHLBI | 34.9%22 of 63 | 44.5%49 of 110 | 33.7%56 of 166 | 28.8%40 of 139 |
| NIAID | 35.5%11 of 31 | 51.6%33 of 64 | 42.9%15 of 35 | 32.3%30 of 93 |
| NICHD | 27.3%3 of 11 | 23.8%5 of 21 | 38.2%29 of 76 | 22.2%20 of 90 |
| NIDA | 35.9%23 of 64 | 37.5%3 of 8 | 44.2%23 of 52 | 20.4%10 of 49 |
| NIEHS | 28.6%2 of 7 | 40.0%2 of 5 | 100.0%1 of 1 | 27.9%12 of 43 |
| NIBIB | 100.0%1 of 1 | 66.7%2 of 3 | 0.0%0 of 1 | 31.0%9 of 29 |
| NIAMS | 8.3%2 of 24 | 42.4%14 of 33 | 25.9%7 of 27 | 12.8%5 of 39 |
| NIAAA | 36.4%8 of 22 | 33.3%1 of 3 | 25.0%2 of 8 | 29.0%9 of 31 |
| NIDDK | 32.0%31 of 97 | 36.2%21 of 58 | 36.3%29 of 80 | 21.5%14 of 65 |
| NINDS | 42.9%3 of 7 | 30.5%18 of 59 | 28.0%23 of 82 | 18.5%27 of 146 |
| NIMH | 11.9%12 of 101 | 25.0%5 of 20 | 20.0%27 of 135 | 6.1%6 of 98 |
| NINR | 12.5%1 of 8 | none | 14.3%1 of 7 | 14.3%1 of 7 |
| NCI | 17.3%9 of 52 | 9.3%20 of 214 | none | 19.2%64 of 334 |
| NLM | none | none | none | 0.0%0 of 8 |
| NIA | 14.4%16 of 111 | 27.8%5 of 18 | 15.5%11 of 71 | 7.8%14 of 179 |
| NHGRI | 60.0%3 of 5 | 20.0%1 of 5 | none | 28.0%7 of 25 |
| NCCIH | 0.0%0 of 4 | 0.0%0 of 1 | 23.1%3 of 13 | 0.0%0 of 2 |
| NIMHD | 2.6%1 of 39 | 33.3%2 of 6 | 16.1%5 of 31 | 12.5%2 of 16 |
NIH, FY2025
NIH-wide in FY2025: F30 32.1%, F31 23.5% and F32 26.4%. Several institutes don't take every fellowship type, which shows here as "none." Gray cells have fewer than 20 applications.
| Institute | F30 | F31 | F32 |
|---|---|---|---|
| NIGMS | 66.7%2 of 3 | 39.1%18 of 46 | 30.1%52 of 173 |
| NIDCR | 62.5%5 of 8 | 26.3%10 of 38 | 62.5%5 of 8 |
| NEI | 31.6%6 of 19 | 31.5%23 of 73 | 30.8%8 of 26 |
| NIDCD | 72.7%8 of 11 | 44.8%30 of 67 | 23.3%10 of 43 |
| NHLBI | 34.4%32 of 93 | 34.3%115 of 335 | 35.0%49 of 140 |
| NIAID | 39.4%43 of 109 | 25.5%117 of 459 | 34.3%49 of 143 |
| NICHD | 42.9%21 of 49 | 25.0%54 of 216 | 40.5%30 of 74 |
| NIDA | 60.0%9 of 15 | 41.8%46 of 110 | 45.0%9 of 20 |
| NIEHS | 16.7%1 of 6 | 27.5%19 of 69 | 0.0%0 of 7 |
| NIBIB | 0.0%0 of 2 | 11.1%1 of 9 | 27.3%3 of 11 |
| NIAMS | 37.5%3 of 8 | 18.9%23 of 122 | 16.3%7 of 43 |
| NIAAA | 25.0%2 of 8 | 23.3%20 of 86 | 29.4%5 of 17 |
| NIDDK | 39.6%21 of 53 | 18.5%47 of 254 | 26.4%24 of 91 |
| NINDS | 40.0%10 of 25 | 27.3%143 of 523 | 24.7%20 of 81 |
| NIMH | 28.6%10 of 35 | 17.7%41 of 232 | 14.3%12 of 84 |
| NINR | 100.0%1 of 1 | 23.1%6 of 26 | 0.0%0 of 1 |
| NCI | 25.1%57 of 227 | 15.2%92 of 605 | 17.1%24 of 140 |
| NLM | none | 7.7%1 of 13 | none |
| NIA | 12.5%10 of 80 | 13.4%35 of 262 | 10.9%10 of 92 |
| NHGRI | 0.0%0 of 1 | 14.8%4 of 27 | 12.5%1 of 8 |
| NCCIH | 100.0%2 of 2 | 33.3%4 of 12 | 33.3%1 of 3 |
| NIMHD | 20.0%1 of 5 | 0.0%0 of 23 | 0.0%0 of 5 |
NSF
NSF funded 19% of competitive proposals in FY2025, its lowest rate in the five years below. As of October 1, 2026, neither NSF's FY2027 budget request nor its directorate pages give FY2025 rates by directorate, so the directorate view stops at FY2024. Proposals count in the year NSF decides them, not the year they arrive.
| Agency | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| All NSF | 26%11,349 of 43,617 | 28%10,971 of 39,143 | 29%11,058 of 38,342 | 26%10,591 of 40,454 | 19%8,377 of 43,532 |
Source: NSF FY2025 Agency Financial Report, Table 1.1.
| Directorate | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|---|
| BIOBiological Sciences | 34% | 36% | 30% | 27% | 24% | 19% |
| CISEComputer and Information Science and Engineering | 23% | 25% | 24% | 28% | 29% | 22% |
| EDUSTEM Education | 22% | 23% | 20% | 24% | 27% | 24% |
| ENGEngineering | 26% | 26% | 20% | 24% | 25% | 23% |
| GEOGeosciences | 37% | 42% | 45% | 41% | 44% | 36% |
| MPSMathematical and Physical Sciences | 30% | 30% | 30% | 34% | 33% | 27% |
| SBESocial, Behavioral and Economic Sciences | 23% | 25% | 23% | 22% | 23% | 19% |
| TIPTechnology, Innovation and Partnerships | n/a | n/a | n/a | 24% | 29% | not published |
| OIAOffice of Integrative Activities | 45% | 36% | 27% | 24% | 24% | not published |
| OISEOffice of International Science and Engineering | 14% | 17% | 29% | 30% | 25% | not published |
FY2019 to FY2023: NSF Merit Review Digest, FY2023, Table 1 series. FY2024: each directorate's funding-rate page. TIP was created in FY2022.
| Directorate | Division | Proposals | Awards | Funding rate |
|---|---|---|---|---|
| BIO | Biological Infrastructure (DBI) | 878 | 113 | 13% |
| BIO | Environmental Biology (DEB) | 827 | 197 | 24% |
| BIO | Integrative Organismal Systems (IOS) | 1,325 | 248 | 19% |
| BIO | Molecular and Cellular Biosciences (MCB) | 746 | 168 | 23% |
| CISE | Computing and Communication Foundations (CCF) | 1,120 | 311 | 28% |
| CISE | Computer and Network Systems (CNS) | 2,148 | 473 | 22% |
| CISE | Information and Intelligent Systems (IIS) | 2,122 | 317 | 15% |
| CISE | Advanced Cyberinfrastructure (OAC) | 701 | 229 | 33% |
| EDU | Graduate Education (DGE) | 526 | 106 | 20% |
| EDU | Research on Learning in Formal and Informal Settings (DRL) | 1,546 | 229 | 15% |
| EDU | Undergraduate Education (DUE) | 1,728 | 486 | 28% |
| EDU | Equity for Excellence in STEM (EES) | 556 | 221 | 40% |
| ENG | Chemical, Bioengineering, Environmental and Transport Systems (CBET) | 1,679 | 479 | 29% |
| ENG | Civil, Mechanical and Manufacturing Innovation (CMMI) | 2,337 | 375 | 17%* |
| ENG | Electrical, Communications and Cyber Systems (ECCS) | 1,013 | 264 | 26% |
| ENG | Engineering Education and Centers (EEC) | 333 | 111 | 33% |
| ENG | Emerging Frontiers and Multidisciplinary Activities (EFMA) | 287 | 24 | 8% |
| GEO | Atmospheric and Geospace Sciences (AGS) | 576 | 266 | 46% |
| GEO | Earth Sciences (EAR) | 867 | 286 | 33% |
| GEO | Ocean Sciences (OCE) | 604 | 235 | 39% |
| GEO | Polar Programs (OPP) | 352 | 106 | 30% |
| GEO | Research, Innovation, Synergies and Education (RISE) | 517 | 163 | 32% |
| MPS | Astronomical Sciences (AST) | 1,027 | 184 | 18% |
| MPS | Chemistry (CHE) | 1,143 | 382 | 33% |
| MPS | Materials Research (DMR) | 1,231 | 306 | 25% |
| MPS | Mathematical Sciences (DMS) | 2,533 | 650 | 26% |
| MPS | Office of Strategic Initiatives (OSI) | 153 | 33 | 22% |
| MPS | Physics (PHY) | 627 | 285 | 45% |
| SBE | Behavioral and Cognitive Sciences (BCS) | 1,219 | 206 | 17% |
| SBE | Social and Economic Sciences (SES) | 1,159 | 229 | 20% |
| SBE | SBE Office of Multidisciplinary Activities (SMA) | 243 | 69 | 28% |
NSF now redirects the CISE, ENG and GEO funding-rate pages to its general statistics dashboard, so those rows link to the Internet Archive copy of NSF's own page. * Civil, Mechanical and Manufacturing Innovation (CMMI): NSF shows 17%, but its own counts give 16.0%.
Before you quote these
Methods
Every figure comes from NIH's or NSF's own tables and is checked against its source before publication.
Cite this dataset
Grantsights. NIH and NSF Funding Odds Tracker. Updated October 1, 2026. https://grantsights.com/research/nih-nsf-funding-odds.
License: CC BY 4.0. Free to reuse with attribution.
Go deeper
Looking for an open opportunity rather than odds? Search current grants.
Source trust
Data pages show source families, update cadence, and what Grantsights adds beyond public listings.
Printed from grantsights.com. Check the official notice before you apply.